These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7116300)

  • 1. Toxicity of very high dose nitrosourea administration.
    Breeden JH; Vollmer JT; Twomey PL
    Cancer; 1982 Nov; 50(9):1728-33. PubMed ID: 7116300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methyl CCNU therapy linked leukemia.
    Shetty MR
    Cancer Chemother Pharmacol; 1981; 6(2):199. PubMed ID: 7307237
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase I-II study of ftorafur and methyl-CCNU in advanced colorectal cancer.
    Belt RJ; Stephens R
    Cancer; 1979 Sep; 44(3):869-72. PubMed ID: 383275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methyl-CCNU in malignant melanoma--a divided dose schedule of administration.
    Wittes RE; Hong WK; Gatchell L; Krakoff IH; Golbey RB
    Oncology; 1977; 34(1):45-6. PubMed ID: 865760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukemia after therapy with methyl CCNU.
    Cohen RJ
    N Engl J Med; 1980 Jan; 302(2):120. PubMed ID: 6927914
    [No Abstract]   [Full Text] [Related]  

  • 6. Interstitial pulmonary fibrosis as a complication of prolonged methyl-CCNU therapy.
    Lee W; Moore RP; Wampler GL
    Cancer Treat Rep; 1978 Sep; 62(9):1355-8. PubMed ID: 688278
    [No Abstract]   [Full Text] [Related]  

  • 7. 5FU infusion with mitomycin-C versus 5 FU infusion with methyl-CCNU in the treatment of advanced colon cancer: a Southwest Oncology Group Study.
    Buroker T; Kim PN; Groppe C; McCracken J; O'Bryan R; Panettiere F; Coltman C; Bottomley R; Wilson H; Bonnet J; Thigpen T; Vaitkevicius VK; Hoogstraten B; Heilbrun L
    Cancer; 1978 Sep; 42(3):1228-33. PubMed ID: 359121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of 5-fluorouracil, methyl-CCNU, and daunorubicin in colorectal cancer: a Cancer and Leukemia Group B study.
    White LA; Perry MC; Kardinal CG; Kennedy BJ; Weiss RB; Carey RW
    Cancer Treat Rep; 1979 Feb; 63(2):215-7. PubMed ID: 445497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case report: acute leukemia after semustine (methyl-CCNU) therapy.
    Uphouse WJ; Oishi N
    Cancer Treat Rep; 1982 Jul; 66(7):1593-4. PubMed ID: 6953997
    [No Abstract]   [Full Text] [Related]  

  • 10. Pulmonary fibrosis associated with low-dose adjuvant methyl-CCNU.
    Block M; Lachowiez RM; Rios C; Hirschl S
    Med Pediatr Oncol; 1990; 18(3):256-60. PubMed ID: 2329971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukemia after adjuvant chemotherapy with semustine (methyl-CCNU)--evidence of a dose-response effect.
    Boice JD; Greene MH; Killen JY; Ellenberg SS; Fraumeni JF; Keehn RJ; McFadden E; Chen TT; Stablein D
    N Engl J Med; 1986 Jan; 314(2):119-20. PubMed ID: 3941685
    [No Abstract]   [Full Text] [Related]  

  • 12. Iv methyl-CCNU and ftorafur with or without methanol-extracted residue of BCG for metastatic adenocarcinoma of the colon.
    Diggs CH; Wiernik PH; Smyth AC
    Cancer Treat Rep; 1977 Nov; 61(8):1581-3. PubMed ID: 336200
    [No Abstract]   [Full Text] [Related]  

  • 13. 5-Fluorouracil, 1,3-bis(2-chloroethyl)-1-nitrosourea, and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea: effect on the human granulopoietic system.
    Lohrmann HP; Lepp KA; Schreml W
    J Natl Cancer Inst; 1982 Apr; 68(4):541-7. PubMed ID: 6951071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized comparison of two dosage schedules of methyl CCNU: three-week versus six-week treatments.
    Taylor SG; DeWys WD; Perlia CP; Wolter J; Slayton RE; Kosova LA; Khandekar JD
    Cancer; 1979 Sep; 44(3):824-30. PubMed ID: 383272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrotoxicity of methyl-CCNU.
    Nichols WC; Moertel CG
    N Engl J Med; 1979 Nov; 301(21):1181. PubMed ID: 492286
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of advanced colorectal cancer with methyl-CCNU plus 5-day 5-fluorouracil infusion.
    Kane RC; Cashdollar MR; Bernath AM
    Cancer Treat Rep; 1978 Oct; 62(10):1521-5. PubMed ID: 709554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of ftorafur with mitomycin C versus ftorafur with methyl-CCNU in untreated colorectal cancer.
    Buroker T; Wojtaszak B; Dindogru A; DeMattia M; Baker L; Groth C; Vaitkevicius VK
    Cancer Treat Rep; 1978 May; 62(5):689-92. PubMed ID: 350398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Qualitative and quantitative toxicity of sublethal doses of methyl-CCNU in BDF1 mice.
    Denine EP; Harrison SD; Peckham JC
    Cancer Treat Rep; 1977; 61(3):409-17. PubMed ID: 872140
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination with 5-fluorouracil, methyl-CCNU and beta-2-deoxythioguanosine in advanced colo-rectal adenocarcinoma.
    Cedermark BJ; Kaufman JH; Douglass HO; Mittelman A
    Clin Oncol; 1977 Mar; 3(1):27-31. PubMed ID: 862274
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase I trial of ftorafur combined with mitomycin C or methyl-CCNU in gastrointestinal cancers.
    Buroker T; Baker L; Correa J; Schwartz LA; Vailtkevicius VK
    Cancer Treat Rep; 1977; 61(3):463-7. PubMed ID: 326403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.